WS #13312
The dominant theme remains US-Iran de-escalation, which is STABLE-to-DE-ESCALATING but with a key contradiction: Iran denies holding talks with the US, contradicting Trump's claim that negotiations begin Monday. This is corroborated by multiple sources (GDELT, Al Jazeera, Reuters via Bluesky). Oil prices have plunged ~5-6% (WTI ~$79, Brent ~$83) on de-escalation hopes, but Iran's denial and continued tanker attacks (UKMTO explosion near Oman) introduce residual risk. OPEC+ approved a 188k bpd increase for September, adding bearish pressure on oil. The dollar is tumbling after Treasury intervention to buy yen, with US/Japan warning of more action. In corporate news, AstraZeneca-Bristol Myers Squibb merger talks continue (BMY up, AZN down), and a new M&A: Atkore to be acquired by Prysmian at $95/share (+28% premarket), and Curium to buy Lantheus for up to $114.50/share. Palantir reports after the bell today; stock is down 40% from peak, and a BUY signal was issued. Strategy (MSTR) sold another 1,638 BTC (~$105M), adding to bitcoin bearish pressure (BTC ~$62,500).
Topics
Key developments
- Iran denies holding talks with US, contradicting Trump's claim of imminent negotiations
- Oil prices plunge 5-6% on de-escalation hopes; OPEC+ approves another output increase
- AstraZeneca and Bristol Myers Squibb in preliminary $400B merger talks
- Atkore to be acquired by Prysmian at $95/share all-cash
- Curium to acquire Lantheus for up to $114.50/share cash
- Strategy sells another 1,638 BTC (~$105M), adding to bitcoin bearish pressure
- US dollar tumbles after Treasury intervention to buy yen; US and Japan warn of more action
- Palantir reports earnings after the bell; stock down 40% from peak, BUY signal issued